{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T22:40:14Z","timestamp":1727390414611},"reference-count":25,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","valueinhealthjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jval.2024.06.006","type":"journal-article","created":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T16:29:46Z","timestamp":1720283386000},"page":"1382-1392","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predicting the Population Health Economic Impact of Current and New Cancer Treatments for Colorectal Cancer: A Data-Driven Whole Disease Simulation Model for Predicting the Number of Patients with Colorectal Cancer by Stage and Treatment Line in Australia"],"prefix":"10.1016","volume":"27","author":[{"given":"Koen","family":"Degeling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yat Hang","family":"To","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Trapani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophy","family":"Athan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten J.","family":"IJzerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny","family":"Franchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jval.2024.06.006_bib1","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jamaoncol.2022.7826","article-title":"Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050","volume":"9","author":"Chen","year":"2023","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.jval.2024.06.006_bib2","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1158\/1055-9965.EPI-19-1534","article-title":"Medical care costs associated with cancer survivorship in the United States","volume":"29","author":"Mariotto","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"10.1016\/j.jval.2024.06.006_bib3","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3390\/curroncol28020117","article-title":"The out-of-pocket cost burden of cancer care-A systematic literature review","volume":"28","author":"Iragorri","year":"2021","journal-title":"Curr Oncol"},{"issue":"4","key":"10.1016\/j.jval.2024.06.006_bib4","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.19.01963","article-title":"Trends in the cost of cancer care: beyond drugs","volume":"38","author":"Laviana","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.jval.2024.06.006_bib5","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1002\/cncr.28214","article-title":"Lost productivity and burden of illness in cancer survivors with and without other chronic conditions","volume":"119","author":"Dowling","year":"2013","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.jval.2024.06.006_bib6","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw205","article-title":"Financial hardships experienced by cancer survivors: a systematic review","volume":"109","author":"Altice","year":"2017","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.jval.2024.06.006_bib7","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s40273-019-00806-4","article-title":"Estimating lifetime benefits associated with immuno-oncology therapies: challenges and approaches for overall survival extrapolations","volume":"37","author":"Ouwens","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"10.1016\/j.jval.2024.06.006_bib8","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S2468-1253(21)00147-3","article-title":"The economic burden of colorectal cancer across Europe: a population-based cost-of-illness study","volume":"6","author":"Henderson","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"21","key":"10.1016\/j.jval.2024.06.006_bib10","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1056\/NEJMsb1013826","article-title":"Bending the cost curve in cancer care","volume":"364","author":"Smith","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.jval.2024.06.006_bib14","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.3390\/cancers14194799","article-title":"Significant Rise of Colorectal Cancer Incidence in Younger Adults and Strong Determinants: 30 years Longitudinal Differences between under and over 50s","volume":"14","author":"Sifaki-Pistolla","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"16","key":"10.1016\/j.jval.2024.06.006_bib15","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMra2200869","article-title":"Increasing incidence of early-onset colorectal cancer","volume":"386","author":"Sinicrope","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.jval.2024.06.006_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201552","article-title":"Health services costs for cancer care in Australia: estimates from the 45 and Up Study","volume":"13","author":"Goldsbury","year":"2018","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jval.2024.06.006_bib17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2217\/cer-2021-0296","article-title":"Health technology assessments and real-world evidence: tell us what you want, what you really, really want","volume":"11","author":"Griesinger","year":"2022","journal-title":"J\u00a0Comp Eff Res"},{"issue":"4","key":"10.1016\/j.jval.2024.06.006_bib18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jval.2023.01.010","article-title":"Using real-world data in the health technology assessment of pharmaceuticals: strengths, difficulties, and a pragmatic way forward","volume":"26","author":"Akehurst","year":"2023","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2024.06.006_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40900-020-00248-9","article-title":"Patients and public are important stakeholders in health technology assessment but the level of involvement is low \u2013 a call to action","volume":"7","author":"Wale","year":"2021","journal-title":"Res Involvement Engagement"},{"key":"10.1016\/j.jval.2024.06.006_bib20","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.canep.2018.09.008","article-title":"Matching the model with the evidence: comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patients","volume":"57","author":"Degeling","year":"2018","journal-title":"Cancer Epidemiol"},{"issue":"11","key":"10.1016\/j.jval.2024.06.006_bib22","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/imj.12230","article-title":"Developing a national database for metastatic colorectal cancer management: perspectives and challenges","volume":"43","author":"Field","year":"2013","journal-title":"Int Med J"},{"issue":"6","key":"10.1016\/j.jval.2024.06.006_bib23","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jval.2012.04.013","article-title":"Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--4","volume":"15","author":"Karnon","year":"2012","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2024.06.006_bib24","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0272989X18814770","article-title":"Comparing strategies for modeling competing risks in discrete-event simulations: a simulation study and illustration in colorectal cancer","volume":"39","author":"Degeling","year":"2019","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2024.06.006_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1255021","article-title":"Implementing competing risks in discrete event simulation: the event-specific probabilities and distributions approach","volume":"14","author":"Franchini","year":"2023","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.jval.2024.06.006_bib26","first-page":"1","article-title":"flexsurv: a platform for parametric survival modeling in R","volume":"70","author":"Jackson","year":"2016","journal-title":"J\u00a0Stat Softw"},{"issue":"3","key":"10.1016\/j.jval.2024.06.006_bib27","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00180-010-0217-1","article-title":"maxLik: a package for maximum likelihood estimation in R","volume":"26","author":"Henningsen","year":"2011","journal-title":"Comp Stat"},{"key":"10.1016\/j.jval.2024.06.006_bib29","doi-asserted-by":"crossref","first-page":"100441","DOI":"10.1016\/j.jcpo.2023.100441","article-title":"A tailored approach to horizon scanning for cancer medicines","volume":"38","author":"Soon","year":"2023","journal-title":"J Cancer Policy"},{"issue":"23","key":"10.1016\/j.jval.2024.06.006_bib32","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.jval.2024.06.006_bib34","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1177\/0272989X20944869","article-title":"Validation of microsimulation models against alternative model predictions and long-term colorectal cancer incidence and mortality outcomes of randomized controlled trials","volume":"40","author":"Lew","year":"2020","journal-title":"Med Decis Making"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524027451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524027451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T22:17:12Z","timestamp":1727389032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301524027451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1098301524027451"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2024.06.006","relation":{},"ISSN":["1098-3015"],"issn-type":[{"type":"print","value":"1098-3015"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting the Population Health Economic Impact of Current and New Cancer Treatments for Colorectal Cancer: A Data-Driven Whole Disease Simulation Model for Predicting the Number of Patients with Colorectal Cancer by Stage and Treatment Line in Australia","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2024.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}